10.07.2013 • NewsAstraZenecaCancer researchcancer

AstraZeneca Signs Up First Cambridge Partners In Cancer Research

British pharmaceutical company AstraZeneca has agreed its first research partnerships in Cambridge for cancer treatments ahead of its relocation to the university city by 2016.

The firm said it would work on three oncology projects with Cancer Research UK and the University of Cambridge's department of oncology at Addenbrooke's Hospital, located next to the site for its new research center and headquarters. The projects include using blood tests to monitor tumors instead of biopsies, potential drugs for prostate cancer, and new approaches for pancreatic cancer, which has a very poor prognosis and few treatments available, the company said on Tuesday. AstraZeneca's move to Cambridge is the centerpiece of $2.3 billion restructuring plan unveiled by new chief executive Pascal Soriot in March. It confirmed last month that it would be based at the Cambridge Biomedical Campus.

Susan Galbraith, head of AstraZeneca's Oncology Innovative Medicines Unit, said it was fitting that the first collaborations since announcing the move were in cancer because its Cambridge facility will become its largest center for oncology research.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.